Key result
Second-generation CETP inhibitors lower LDL-C by ~43 mg/dL vs. placebo in HeFH.
Why the study?
Second-generation CETP inhibitors may provide additional lipid-lowering benefit when added to background lipid-lowering therapy in patients with HeFH, prompting an evaluation of their efficacy and safety versus placebo.
Do second-generation CETP inhibitors reduce LDL-C compared with placebo in adults with heterozygous familial hypercholesterolemia receiving stable background lipid-lowering therapy?
Meta-Analysis (n=728)
Do second-generation CETP inhibitors reduce LDL-C compared with placebo in adults with heterozygous familial hypercholesterolemia receiving stable background lipid-lowering therapy?
Second-generation CETP inhibitors significantly lower LDL-C, non-HDL-C, apolipoprotein B, and lipoprotein(a) while increasing LDL-C target attainment in patients with heterozygous familial hypercholesterolemia without short- to medium-term safety signals.
Answers are grounded in this paper and cite their sources.
Supports LDL-C lowering with second-generation CETP inhibitors in HeFH on background therapy; extends RCT evidence to this high-risk population.
Introduction: Heterozygous familial hypercholesterolemia (HeFH) is a common inherited lipid disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) and increased cardiovascular risk. Second-generation cholesteryl ester transfer protein (CETP) inhibitors may provide additional lipid-lowering benefit when added to background lipid-lowering therapy. We evaluated the efficacy and safety of second-generation CETP inhibitors versus placebo in adults with HeFH receiving stable lipid-lowering therapy. Methods: PubMed, EMBASE, Cochrane Library, Scopus, and Web of Science were searched from inception to May 10, 2026, for randomized controlled trials comparing second-generation CETP inhibitors with placebo in adults with HeFH. The primary outcome was change in LDL-C. Secondary outcomes included LDL-C goal attainment, non-HDL-C, apolipoprotein B, lipoprotein(a), HDL-C, apolipoprotein A1, triglycerides, and adverse events. Random-effects meta-analysis was performed using R software. Results: Three randomized controlled trials including 728 participants were included. Compared with placebo, CETP inhibitors significantly reduced LDL-C (MD -43.38 mg/dL, 95% CI -52.85 to -33.91; P<0.001; Figure A ), non-HDL-C (MD -48.77 mg/dL, 95% CI -60.46 to -37.09), apolipoprotein B (MD -23.45 mg/dL, 95% CI -32.59 to -14.30), and lipoprotein(a) (MD -34.92 nmol/L, 95% CI -57.48 to -12.35). CETP inhibitors also increased HDL-C and apolipoprotein A1. Patients receiving CETP inhibitors were more likely to achieve LDL-C <100 mg/dL (RR 2.56, 95% CI 1.45 to 4.53; P=0.001) and LDL-C <70 mg/dL (RR 5.65, 95% CI 2.75 to 11.58; P<0.001; Figure B ). No significant difference was observed for triglycerides or overall adverse events. Heterogeneity was moderate to high for several lipid outcomes. Conclusion: Second-generation CETP inhibitors significantly improve LDL-C and multiple atherogenic lipid parameters in adults with HeFH receiving background lipid-lowering therapy. They also increase the likelihood of achieving clinically relevant LDL-C targets without an obvious short- to medium-term safety signal. Larger and longer-term randomized trials are needed to confirm cardiovascular outcome benefit and long-term safety.
No takes yet. Share an insight, caveat, or question.
Gadelmawla et al. (2026) conducted a meta-analysis in Heterozygous familial hypercholesterolemia (HeFH) (n=728). Second-generation cholesteryl ester transfer protein (CETP) inhibitors vs. Placebo added to stable background lipid-lowering therapy was evaluated on Change in LDL-C (MD -43.38 mg/dL, 95% CI -52.85 to -33.91, p=<0.001). Second-generation CETP inhibitors significantly reduced LDL-C compared with placebo in adults with HeFH (MD -43.38 mg/dL; 95% CI -52.85 to -33.91; P<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: